Document is current
Any future updates will be listed below
-
Authors
Kovacech, Branislav
Cullen, Nicholas C.
Novak, Petr
Hanes, Jozef
Kontsekova, Eva
Katina, Stanislav
Parrak, Vojtech
Fresser, Michal
Vanbrabant, Jeroen
Feldman, Howard H.
Winblad, Bengt
Stoops, Erik
Vanmechelen, Eugeen
Zilka, Norbert
- License Information
-
More Information
Article History
Received: 13 September 2024
Accepted: 11 November 2024
First Online: 23 November 2024
Declarations
:
: The ADAMANT study protocol (provided with the Statistical Analysis Plan in Clinical Trial Material Supplement) was approved by the appropriate ethics committees and competent authorities []. All patients and their caregivers provided written informed consent before the study procedures.
: Not applicable.
: All authors affiliated with AXON Neuroscience SE or AXON Neuroscience R&D Services SE received salaries from their respective companies. Petr Novak received payments from F. Hoffmann-La Roche AG. The investigators’ institutions received reimbursement on a per-patient per-visit basis. Bengt Winblad received personal fees from Axon Neuroscience for participating in SAB and DSMB. Howard H Feldman reports serving as a consultant to AXON Neuroscience through a service agreement with UC San Diego. No funds have been personally received, and no funding for this manuscript has been received. All the authors affiliated with ADx NeuroSciences received a salary. Eugeen Vanmechelen is a cofounder of the company.
